Emergent BioSolutions (NYSE:EBS) Rating Reiterated by Rodman & Renshaw

Emergent BioSolutions (NYSE:EBS – Get a Free Report)Its stock had a “buy” rating reiterated by research analysts at Rodman & Renshaw in a note issued to investors on Friday, Benzinga reports. They currently have a $16.00 target price on the biopharmaceutical company’s stock. Rodman & Renshaw’s price objective would indicate a potential upside of 103.30% from the company’s previous close.

Separately, Benchmark reissued a “buy” rating and set a $8.00 price objective on shares of Emergent BioSolutions in a research note on Friday, August 16th.

View the latest stock analysis on emerging biological solutions

Emergent BioSolutions Stock Performance

NYSE:EBS opened at $7.87 on Friday. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.06, and a quick ratio of 0.54. The company has a fifty day simple moving average of $9.68 and a two hundred day simple moving average of $6.06. Emergent BioSolutions has a 1 year low of $1.42 and a 1 year high of $15.10. The company has a market cap of $416.40 million, a P/E ratio of -0.71 and a beta of 1.60.

Emergent BioSolutions (NYSE:EBS – Get Free Report ) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($2.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($1.35). Emergent BioSolutions had a negative return on equity of 34.38% and a negative net margin of 53.26%. The company had revenue of $254.70 million during the quarter, compared to the consensus estimate of $199.47 million. During the same period in the previous year, the company earned ($1.06) earnings per share. On average, analysts expect that Emergent BioSolutions will post -1.98 earnings per share for the current year.

Institutional investors are stepping in on emerging biosolutions

Several hedge funds have recently added to or reduced their stakes in the company. Truist Financial Corp boosted its holdings in shares of Emergent BioSolutions by 12.3% in the second quarter. Truist Financial Corp now owns 131,526 shares of the biopharmaceutical company’s stock worth $897,000 after purchasing an additional 14,360 shares during the period. Millennium Management LLC boosted its holdings in shares of Emergent BioSolutions by 5.8% in the second quarter. Millennium Management LLC now owns 946,302 shares of the biopharmaceutical company’s stock worth $6,454,000 after buying an additional 52,144 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Emergent BioSolutions in the second quarter valued at about $485,000. Squarepoint Ops LLC acquired a new position in Emergent BioSolutions during the second quarter valued at approximately $1,576,000. Finally, Point72 DIFC Ltd acquired a new position in Emergent BioSolutions in the second quarter valued at about $406,000. Institutional investors own 78.40% of the company’s shares.

About Emergent BioSolutions

(Get a free report)

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate and natural threats to public health in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opiate overdose; Vaxchora vaccine to prevent cholera; Oral vaccine Vivotif for the prevention of typhoid fever; Anthracil for the treatment of anthrax by inhalation; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Injectable Raxibacumab for the treatment and prophylaxis of inhalational anthrax.

Further reading

Receive daily news and reviews for Emergent BioSolutions – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Emergent BioSolutions and related companies with MarketBeat.com’s FREE daily email newsletter.